News

NIH Office of Research on Women’s Health Inviting Comments To Inform the Women’s Health Consensus Conference (WHCC)

The National Institutes of Health (NIH) Office of Research on Women’s Health (ORWH) is planning a Women’s Health Consensus Conference (WHCC) in October 2021, in response to a Congressional request to address NIH research efforts related to women’s health research as well as the following specific conditions, rising maternal morbidity and mortality rates, increasing rates of chronic debilitating conditions in women, and stagnant cervical cancer survival rates. The ORWH is seeking comments and testimonies from the extramural scientific community, professional societies, and the general public regarding the topics mentioned above to assist with identifying research gaps, pitfalls in clinical practices, and obtaining real-life testimonial experiences (direct or indirect) caused by any or all of the listed public health issues.

The Women’s Health Consensus Conference (WHCC) Request for Information is open for public comment through September 15, 2021. Comments must be received by September 15, 2021, to ensure consideration. Comments received after the public comment period has closed may be considered by the Office of Research on Women’s Health.

Submissions must be sent electronically to Elizabeth Barr, Ph.D., WHCC@od.nih.gov.

FOR ADDITIONAL INFORMATION CONTACT:

Questions about this request for information should be directed to Elizabeth Barr, Ph.D., Office of Research on Women’s Health, 6707 Democracy Boulevard, Suite 400, Bethesda, MD 20817, WHCC@od.nih.gov, 301-402-7895.

Further details also available here.

Recent News

03/04/2026

RBIA Welcomes Chip Bobbert as Director of Innovation

The Roanoke Blacksburg Innovation Alliance is pleased to welcome Chip Bobbert, new Director of Innovation, to the team. The Director of Innovation is a new position, and Bobbert began the role on February 2 with a focus on working across the RBIA portfolio of organizations and programs to lead regional innovation strategy, founder and investor

03/02/2026

Learn about Fairfax FIRST

The Fairfax Innovation for Research, Science, and Technology (FIRST) program is intended to provide participants with the physical address needed for funding applications, while alleviating the financial burden of a lease before substantial funding is received. FIRST supports early-stage entities that seek to advance the development or application of emerging technologies. Acceptance into the program

02/25/2026

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to treating MASH, obesity, and associated cardiometabolic diseases, today announced the appointment of Jorge Bartolome as Chief Executive Officer and member of the Board. He succeeds Allen Cunningham, a co-founder who will move to the role of Chief Operating Officer. Mr. Bartolome has over 25 years of